Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Ginkgo Bioworks Holdings
DNA
DNA
Ginkgo Bioworks Holdings
Intensifying Competition And Regulatory Burdens Will Hurt Synthetic Biology Revenue
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
09 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
109.2% overvalued
intrinsic discount
16 Aug
US$12.55
Loading
1Y
54.0%
7D
-4.8%
Author's Valuation
US$6.0
109.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
109.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3b
539m
2019
2021
2023
2025
2027
2028
Revenue US$180.0m
Earnings US$23.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-4.84%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.44%
Calculation
US$23.04m
Earnings '28
x
22.17x
PE Ratio '28
=
US$511.01m
Market Cap '28
US$511.01m
Market Cap '28
/
67.24m
No. shares '28
=
US$7.60
Share Price '28
US$7.60
Share Price '28
Discounted to 2025 @ 8.33% p.a.
=
US$5.98
Fair Value '25
